All Stories

  1. ROTEM-detected hypocoagulability is associated with major non-portal hypertensive bleeding in cirrhosis

    Article • Hepatology Communications, January 2026, Wolters Kluwer Health

    Xavier Verhelst

  2. Isolated IgG elevation in patients with persistently normal transaminases does not affect the outcome of autoimmune hepatitis: or just a little bit?

    Article • JHEP Reports, November 2025, Elsevier

    Xavier Verhelst

  3. Liver transplantation for hepatopulmonary syndrome: a systematic review and meta-analysis

    Article • JHEP Reports, October 2025, Elsevier

    Xavier Verhelst

  4. Mitochondrial dysfunction characterises the multigenerational effects of maternal obesity on MASLD

    Article • JHEP Reports, June 2025, Elsevier

    Xavier Verhelst

  5. The double-edged sword of metabolic and bariatric surgery: extending the biliary limb can trigger bacterial translocation, sepsis, and liver inflammation – an experimental study

    Article • International Journal of Surgery, May 2025, Wolters Kluwer Health

    Xavier Verhelst

  6. Liver transplantation for hepatocellular carcinoma with stem cell features in an adult patient

    Article • Journal of Liver Transplantation, February 2025, Elsevier

    Xavier Verhelst

  7. Diagnostic criteria and long-term outcomes in AIH-PBC variant syndrome under combination therapy

    Article • JHEP Reports, July 2024, Elsevier

    Xavier Verhelst

  8. Editorial: Recompensation in PBC is good. But is it good enough?

    Article • Alimentary Pharmacology & Therapeutics, April 2024, Wiley

    Xavier Verhelst

  9. Validation of a glycomics-based test associated with risk of HCC development in cirrhosis

    Article • February 2024, Cold Spring Harbor Laboratory Press

    Xavier Verhelst

  10. Maternal liver-related symptoms during pregnancy in primary sclerosing cholangitis

    Article • JHEP Reports, January 2024, Elsevier

    Xavier Verhelst

  11. Systematic review: Glycomics as diagnostic markers for hepatocellular carcinoma

    Article • Alimentary Pharmacology & Therapeutics, October 2023, Wiley

    Xavier Verhelst

  12. Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant

    Article • Hepatology Communications, October 2023, Wolters Kluwer Health

    Dr Vishal C Patel, Xavier Verhelst, Dr Antonio Riva

  13. Patients hospitalized with alcohol‐related liver disease and prior bariatric surgery are more prone to develop acute‐on‐chronic liver failure

    Article • Liver International, September 2023, Wiley

    Xavier Verhelst

  14. A remarkable presentation of a massive Budd-Chiari syndrome

    Article • Acta Gastro Enterologica Belgica, September 2023, Universa BV

    Xavier Verhelst

  15. An unusual cause of portal hypertension

    Article • Acta Gastro Enterologica Belgica, September 2023, Universa BV

    Xavier Verhelst

  16. Osteopontin characterizes bile duct–associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis

    Article • Hepatology, August 2023, Wolters Kluwer Health

    Xavier Verhelst

  17. Liver Transplantation for Porto-sinusoidal Vascular Liver Disorder: Long-term Outcome

    Article • Transplantation, May 2023, Wolters Kluwer Health

    Xavier Verhelst

  18. Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one‐year non‐responders and predicts survival

    Article • Liver International, May 2023, Wiley

    Xavier Verhelst

  19. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study

    Article • Hepatology, April 2023, Wolters Kluwer Health

    Xavier Verhelst

  20. Kupffer Cells Contested as Early Drivers in the Pathogenesis of Primary Sclerosing Cholangitis

    Article • American Journal Of Pathology, April 2023, Elsevier

    Xavier Verhelst

  21. Transient Kupffer cell depletion and subsequent replacement by infiltrating monocyte‐derived cells does not alter the induction or progression of hepatocellular carcinoma

    Article • International Journal of Cancer, March 2023, Wiley

    Xavier Verhelst

  22. Meta‐analysis: The impact of light‐to‐moderate alcohol consumption on progressive non‐alcoholic fatty liver disease

    Article • Alimentary Pharmacology & Therapeutics, January 2023, Wiley

    Xavier Verhelst

  23. Ursodeoxycholic Acid Treatment–Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis

    Article • The American Journal of Gastroenterology, December 2022, Wolters Kluwer Health

    Xavier Verhelst

  24. Intensive Lifestyle Management Improves Steatosis and Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease

    Article • Clinical Gastroenterology and Hepatology, October 2022, Elsevier

    Xavier Verhelst

  25. Aminotransferases During Treatment Predict Long-Term Survival in Patients With Autoimmune Hepatitis Type 1: A Landmark Analysis

    Article • Clinical Gastroenterology and Hepatology, August 2022, Elsevier

    Prof. Dr. Bart van Hoek, Xavier Verhelst

  26. Different Models to Predict the Risk of Recurrent Hepatocellular Carcinoma in the Setting of Liver Transplantation

    Article • Cancers, June 2022, MDPI AG

    Xavier Verhelst

  27. 90Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial

    Article • Radiology, June 2022, Radiological Society of North America (RSNA)

    Xavier Verhelst

  28. Impact on follow‐up strategies in patients with primary sclerosing cholangitis

    Article • Liver International, May 2022, Wiley

    Xavier Verhelst

  29. Glycomics-based serum markers as reliable tool for assessment of viral response after treatment with direct-acting antiviral drugs in hepatitis C virus infection

    Article • Acta Clinica Belgica, May 2022, Taylor & Francis

    Xavier Verhelst

  30. Maternal and Perinatal Risk Factors for Pediatric Nonalcoholic Fatty Liver Disease: A Systematic Review

    Article • Clinical Gastroenterology and Hepatology, April 2022, Elsevier

    Xavier Verhelst

  31. Serum Glycomics on Postoperative Day 7 Are Associated With Graft Loss Within 3 Months After Liver Transplantation Regardless of Early Allograft Dysfunction

    Article • Transplantation, October 2021, Wolters Kluwer Health

    Xavier Verhelst

  32. The neurogliovascular unit in hepatic encephalopathy

    Article • JHEP Reports, October 2021, Elsevier

    Xavier Verhelst

  33. Diagnostic and prognostic scoring systems for autoimmune hepatitis : a review

    Article • Acta Gastro Enterologica Belgica, September 2021, Universa BV

    Xavier Verhelst

  34. Focal eosinophilic infiltration of the liver, benign or malignant?

    Article • Clinical Case Reports, August 2021, Wiley

    Xavier Verhelst

  35. Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis

    Article • Clinical Gastroenterology and Hepatology, August 2021, Elsevier

    Xavier Verhelst, Professor Albert Pares

  36. Development and validation of a prognostic score for long‐term transplant‐free survival in autoimmune hepatitis type 1

    Article • United European Gastroenterology Journal, June 2021, Wiley

    Prof. Dr. Bart van Hoek, Xavier Verhelst

  37. The utility of biomarkers in prognosis assessment of patients with acute liver failure

    Article • Hepatology Research, June 2021, Wiley

    Xavier Verhelst

  38. A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis

    Article • The American Journal of Gastroenterology, May 2021, Wolters Kluwer Health

    Xavier Verhelst, Professor Albert Pares

  39. Characterization of the inflammatory microenvironment and hepatic macrophage subsets in experimental hepatocellular carcinoma models

    Article • Oncotarget, March 2021, Impact Journals, LLC

    Xavier Verhelst

  40. Comorbidities and concomitant medications in patients with chronic hepatitis C virus infection receiving second-generation direct-acting antiviral regimens in Belgium : an observational study

    Article • Acta Gastro Enterologica Belgica, February 2021, Universa BV

    Xavier Verhelst

  41. Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure

    Article • Journal of Hepatology, February 2021, Elsevier

    Xavier Verhelst

  42. NOX1 inhibition attenuates the development of a pro‐tumorigenic environment in experimental hepatocellular carcinoma

    Article • Journal of Experimental & Clinical Cancer Research, January 2021, Springer Science + Business Media

    Xavier Verhelst

  43. NOX1 inhibition attenuates the development of a pro-tumorigenic environment in experimental hepatocellular carcinoma

    Article • January 2021, Springer Science + Business Media

    Xavier Verhelst

  44. Health status of patients with autoimmune hepatitis is not affected by the SARS-CoV-2 outbreak in Flanders, Belgium

    Article • Journal of Hepatology, January 2021, Elsevier

    Xavier Verhelst

  45. Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool

    Article • European Journal of Gastroenterology & Hepatology, December 2020, Wolters Kluwer Health

    Xavier Verhelst, Professor Albert Pares

  46. Effect of isoform-specific HIF-1α and HIF-2α antisense oligonucleotides on tumorigenesis, inflammation and fibrosis in a hepatocellular carcinoma mouse model

    Article • Oncotarget, December 2020, Impact Journals, LLC

    Xavier Verhelst

  47. Up to 50% of portal vein thrombosis remains undiagnosed until liver transplantation

    Article • Clinical Transplantation, October 2020, Wiley

    Xavier Verhelst

  48. Vasomodulators and Liver Transplantation for Portopulmonary Hypertension: Evidence From a Systematic Review and Meta‐Analysis

    Article • Hepatology, October 2020, Wolters Kluwer Health

    Xavier Verhelst

  49. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis

    Article • Journal of Hepatology, September 2020, Elsevier

    Xavier Verhelst, Professor Albert Pares

  50. Bariatric Surgery Patients Are at Risk for Alcoholic Liver Disease with Need for Liver Transplantation

    Article • Obesity Surgery, June 2020, Springer Science + Business Media

    Xavier Verhelst

  51. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model

    Article • Metabolism, June 2020, Elsevier

    Xavier Verhelst

  52. Hepatitis C in two general practices in Flanders, Belgium: is there a need to reconsider current screening recommendations?

    Article • Acta Clinica Belgica, May 2020, Taylor & Francis

    Xavier Verhelst

  53. Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis

    Article • Clinical Gastroenterology and Hepatology, March 2020, Elsevier

    Xavier Verhelst, Professor Albert Pares

  54. Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase

    Article • The American Journal of Gastroenterology, February 2020, Wolters Kluwer Health

    Xavier Verhelst, Professor Albert Pares

  55. Protein Glycosylation as a Diagnostic and Prognostic Marker of Chronic Inflammatory Gastrointestinal and Liver Diseases

    Article • Gastroenterology, January 2020, Elsevier

    Xavier Verhelst

  56. Combination of sivelestat and N-acetylcysteine alleviates the inflammatory response and exceeds standard treatment for acetaminophen-induced liver injury

    Article • Journal of Leukocyte Biology, December 2019, Oxford University Press (OUP)

    Xavier Verhelst

  57. Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis

    Article • Journal of Hepatology, November 2019, Elsevier

    Xavier Verhelst

  58. Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response

    Article • Alimentary Pharmacology & Therapeutics, October 2019, Wiley

    Xavier Verhelst, Professor Albert Pares

  59. Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis

    Article • Clinical Gastroenterology and Hepatology, September 2019, Elsevier

    Xavier Verhelst, Professor Albert Pares

  60. Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide

    Article • Gastroenterology, April 2019, Elsevier

    Xavier Verhelst

  61. Angiopoietin‐2 Promotes Pathological Angiogenesis and Is a Therapeutic Target in Murine Nonalcoholic Fatty Liver Disease

    Article • Hepatology, February 2019, Wolters Kluwer Health

    Xavier Verhelst

  62. Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival

    Article • Gastroenterology, January 2019, Elsevier

    Professor Albert Pares, Xavier Verhelst

  63. Endoglycosidase S Enables a Highly Simplified Clinical Chemistry Procedure for Direct Assessment of Serum IgG Undergalactosylation in Chronic Inflammatory Disease

    Article • Molecular & Cellular Proteomics, December 2018, Elsevier

    Xavier Verhelst

  64. Outcome of liver transplantation for hepatopulmonary syndrome: a Eurotransplant experience

    Article • European Respiratory Journal, November 2018, European Respiratory Society (ERS)

    Xavier Verhelst

  65. Secondary Adrenal Insufficiency after Treatment with Budesonide for Autoimmune Hepatitis

    Article • Case Reports in Gastroenterology, October 2018, Karger Publishers

    Xavier Verhelst

  66. Clinical burden of hepatitis E virus infection in a tertiary care center in Flanders, Belgium

    Article • Journal of Clinical Virology, June 2018, Elsevier

    Xavier Verhelst

  67. Placental growth factor inhibition targets pulmonary angiogenesis and represents a novel therapy for hepatopulmonary syndrome in mice

    Article • Hepatology, May 2018, Wiley

    Prof. Dr. Ken R Bracke, Xavier Verhelst

  68. Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history

    Article • Hepatology, April 2018, Wiley

    Xavier Verhelst, Professor Albert Pares

  69. Glycome Patterns of Perfusate in Livers Before Transplantation Associate With Primary Nonfunction

    Article • Gastroenterology, April 2018, Elsevier

    Xavier Verhelst

  70. Endoglycosidase S enables a highly simplified clinical chemistry assay procedure for direct assessment of serum IgG undergalactosylation in chronic inflammatory disease

    Article • February 2018, Cold Spring Harbor Laboratory Press

    Xavier Verhelst

  71. Severe Hepatic and Pulmonary Involvement in Rendu-Osler-Weber Syndrome

    Article • Case Reports in Gastroenterology, January 2018, Karger Publishers

    Xavier Verhelst

  72. Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome

    Article • The American Journal of Gastroenterology, December 2017, Wolters Kluwer Health

    Professor Albert Pares, Xavier Verhelst

  73. Non-alcoholic steatohepatitis induces transient changes within the liver macrophage pool

    Article • Cellular Immunology, December 2017, Elsevier

    Xavier Verhelst

  74. Hepatitis E virus serology and PCR: does the methodology matter?

    Article • Archives of Virology, May 2017, Springer Science + Business Media

    Xavier Verhelst

  75. Refractory subacute steatohepatitis after biliopancreatic diversion

    Article • Hepatology, May 2017, Wiley

    Xavier Verhelst

  76. Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease

    Article • International Journal of Obesity, May 2017, Nature

    Xavier Verhelst

  77. Modulation of the Unfolded Protein Response by Tauroursodeoxycholic Acid Counteracts Apoptotic Cell Death and Fibrosis in a Mouse Model for Secondary Biliary Liver Fibrosis

    Article • International Journal of Molecular Sciences, January 2017, MDPI AG

    Xavier Verhelst

  78. A Glycomics-Based Test Predicts the Development of Hepatocellular Carcinoma in Cirrhosis

    Article • Clinical Cancer Research, December 2016, American Association for Cancer Research (AACR)

    Xavier Verhelst

  79. Combination of tauroursodeoxycholic acid and N-acetylcysteine exceeds standard treatment for acetaminophen intoxication

    Article • Liver International, October 2016, Wiley

    Xavier Verhelst

  80. Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity

    Article • Obesity, October 2016, Wiley

    Xavier Verhelst

  81. Comments on the impact of genotyping method on the subtype distribution of HCV genotype 1

    Article • Journal of Clinical Virology, October 2016, Elsevier

    Xavier Verhelst

  82. Heads or Tails: Genotyping of Hepatitis C Virus Concerning the 2k/1b Circulating Recombinant Form

    Article • International Journal of Molecular Sciences, August 2016, MDPI AG

    Xavier Verhelst

  83. Hypoxia-regulated mechanisms in the pathogenesis of obesity and non-alcoholic fatty liver disease

    Article • Cellular and Molecular Life Sciences, April 2016, Springer Science + Business Media

    Xavier Verhelst

  84. Longitudinal Transient Elastography Measurements Used in Follow-up for Patients with Cystic Fibrosis

    Article • Ultrasound in Medicine & Biology, April 2016, Elsevier

    Xavier Verhelst

  85. The role of macrophages in obesity-driven chronic liver disease

    Article • Journal of Leukocyte Biology, March 2016, Society for Leukocyte Biology

    Xavier Verhelst

  86. Successful Treatment of HCV-associated B-Cell Non-Hodgkin Lymphomas With Direct-acting Antiviral Agents

    Article • Journal of Clinical Gastroenterology, February 2016, Wolters Kluwer Health

    Xavier Verhelst

  87. Placental growth factor inhibition modulates the interplay between hypoxia and unfolded protein response in hepatocellular carcinoma

    Article • BMC Cancer, January 2016, Springer Science + Business Media

    Xavier Verhelst

  88. Quality of life after liver transplantation: State of the art

    Article • World Journal of Hepatology, January 2016, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Xavier Verhelst

  89. Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review

    Article • Obesity Reviews, November 2015, Wiley

    Xavier Verhelst

  90. Tauroursodeoxycholic acid dampens oncogenic apoptosis induced by endoplasmic reticulum stress during hepatocarcinogen exposure

    Article • Oncotarget, September 2015, Impact Journals, LLC

    Xavier Verhelst

  91. Intramuscular hepatitis B immunoglobulins for reinfection control after liver transplantation: a cost-saving alternative

    Article • Journal of Comparative Effectiveness Research, May 2015, Future Medicine

    Xavier Verhelst

  92. Time-Dependent Effect of Hypoxia on Tumor Progression and Liver Progenitor Cell Markers in Primary Liver Tumors

    Article • PLOS One, March 2015, PLOS

    Xavier Verhelst

  93. Hepatopulmonary syndrome and portopulmonary hypertension: recent knowledge in pathogenesis and overview of clinical assessment

    Article • Liver International, February 2015, Wiley

    Xavier Verhelst

  94. Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma

    Article • Oncotarget, November 2014, Impact Journals, LLC

    Xavier Verhelst

  95. Modulation of the unfolded protein response impedes tumor cell adaptation to proteotoxic stress: a PERK for hepatocellular carcinoma therapy

    Article • Hepatology International, October 2014, Springer Science + Business Media

    Xavier Verhelst

  96. Therapeutic effects of artesunate in hepatocellular carcinoma

    Article • European Journal of Gastroenterology & Hepatology, August 2014, Wolters Kluwer Health

    Xavier Verhelst

  97. Role of angiogenic factors/cell adhesion markers in serum of cirrhotic patients with hepatopulmonary syndrome

    Article • Liver International, May 2014, Wiley

    Xavier Verhelst

  98. Cerebellar stroke in a low cardiovascular risk patient associated with sorafenib treatment for fibrolamellar hepatocellular carcinoma

    Article • Clinical Case Reports, December 2013, Wiley

    Xavier Verhelst

  99. Oral vasodilator therapy in patients with moderate to severe portopulmonary hypertension as a bridge to liver transplantation

    Article • European Journal of Gastroenterology & Hepatology, April 2013, Wolters Kluwer Health

    Xavier Verhelst

  100. Pathophysiology and Management of Post Resection Liver Failure

    Article • Acta Chirurgica Belgica, January 2013, Taylor & Francis

    Xavier Verhelst

  101. Biomarkers for the diagnosis of acute cellular rejection in liver transplant recipients: A review

    Article • Hepatology Research, November 2012, Wiley

    Xavier Verhelst

  102. A case of emphysematous gastritis

    Article • Endoscopy, May 2012, Thieme Publishing Group

    Xavier Verhelst

  103. Progressive multifocal leukoencephalopathy in liver transplant recipients: a case report and review of the literature

    Article • Transplant International, December 2010, Wiley

    Xavier Verhelst

  104. Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B

    Article • European Journal of Gastroenterology & Hepatology, April 2010, Wolters Kluwer Health

    Xavier Verhelst

  105. Leflunomide and methotrexate combination therapy in daily clinical practice

    Article • Annals of the Rheumatic Diseases, June 2006, BMJ

    Xavier Verhelst

  106. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis

    Article • Annals of the Rheumatic Diseases, February 2005, BMJ

    Xavier Verhelst